Phase 1 · NCT05548231
A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
A Multiple Dose Escalation Study in Chinese Participants With Overweight BMI or Obesity to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943
CompletedVerified
Trial registry record
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
- ClinicalTrials.gov ID
- NCT05548231
- Indication
- Overweight, Obesity
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 32
- Status
- Completed
- Interventions
- Drug: LY3437943; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 20 Years – 65 Years
- Locations
- 2 sites · China
- Study start
- 24 Oct 2022
- Primary completion
- 27 Jul 2023
- Study completion
- 27 Jul 2023
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 14 Aug 2023
Endpoints
Primary
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943; PK: Area Under the Concentration Versus Time Curve (AUC) of LY3437943